Selim Karayalçın
About
In The Last Decade
Selim Karayalçın
44 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 76
- Hepatology 904
- Epidemiology 860
- Surgery 172
- Infectious Diseases 133
- Molecular Biology 74
Countries citing papers authored by Selim Karayalçın
This map shows the geographic impact of Selim Karayalçın's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Selim Karayalçın with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Selim Karayalçın more than expected).
Fields of papers citing papers by Selim Karayalçın
This network shows the impact of papers produced by Selim Karayalçın. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Selim Karayalçın. The network helps show where Selim Karayalçın may publish in the future.
Co-authorship network of co-authors of Selim Karayalçın
This figure shows the co-authorship network connecting the top 25 collaborators of Selim Karayalçın. A scholar is included among the top collaborators of Selim Karayalçın based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Selim Karayalçın. Selim Karayalçın is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 28 | |
| 3 | 18 | |
| 4 | 21 | |
| 5 | 7 | |
| 6 | 57 | |
| 7 | 3 | |
| 8 | The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. | 6 |
| 9 | 72 | |
| 10 | 95 | |
| 11 | 181 | |
| 12 | 15 | |
| 13 | 6 | |
| 14 | 7 | |
| 15 | 32 | |
| 16 | 16 | |
| 17 | A Placebo Controlled Study of Lamivudine and Interferonalpha-2b in Patients with Chronic Hepatitis B Who PreviouslyFailed Interferon Therapy | 30 |
| 18 | 0 | |
| 19 | 121 | |
| 20 | 28 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.